Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14435919 | 0.79 | AOC3 (0.47) | AOC3ALDH1A1LRRK2CSNK2A1ADORA2A | |
| SCHEMBL5521864 | 0.76 | KDR (0.49) | AOC3 | |
| SCHEMBL21914541 | 0.76 | HSD17B1 (0.53) | AOC3CSNK2A1 | |
| SCHEMBL2405326 | 0.76 | AOC3 (0.44) | AOC3ALDH1A1LRRK2ADORA2AKDM4E | |
| SCHEMBL2406713 | 0.76 | AOC3 (0.48) | AOC3ALDH1A1LRRK2ADORA2AKDM4E | |
| SCHEMBL10200927 | 0.76 | CYP2A6 (0.46) | CYP2A6BRD4ALDH1A3TYRALDH1A1 | |
| SCHEMBL19730877 | 0.76 | APP (0.50) | AOC3ALDH1A1LRRK2CSNK2A1ADORA2A | |
| SCHEMBL2405535 | 0.76 | AOC3 (0.48) | AOC3ALDH1A1LRRK2ADORA2AKDM4E | |
| SCHEMBL146522 | 0.75 | KDR (0.52) | AOC3 | |
| SCHEMBL15193627 | 0.75 | HSD17B1 (0.49) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113613652-B | Benzimidazole compounds and their use in the treatment of alzheimer's disease or huntington's disease | 台湾卫生研究院 | 2022-08-23 | — | — | CN | disclosed |
| CN-113613652-A | Benzimidazole compounds and their use for treating alzheimer's disease or huntington's disease | 台湾卫生研究院 | 2021-11-05 | — | — | CN | disclosed |
| EP-3843724-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | National Health Research Institutes (TW) | 2021-07-07 | — | — | EP | disclosed |
| US-10584120-B1 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-10 | — | — | US | disclosed |
| WO-2020047360-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047360-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-05 | — | — | WO | disclosed |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RES INST (TW) | 2020-03-05 | — | — | US | disclosed |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RES INST (TW) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | GLUL, GLS2, GLS | AOC3 2043/4885CYP2A6 2164/4885BRD4 705/4885 |
| US-10584120-B1 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | GLUL, GLS2, GLS | AOC3 2043/4885CYP2A6 2164/4885BRD4 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.